التفاصيل البيبلوغرافية
| العنوان: |
Effect of thalidomide on gastrointestinal toxic effects of irinotecan. |
| المؤلفون: |
Govindarajan, Rangaswamy, Heaton, Keith M, Broadwater, Ralph, Zeitlin, Andrew, Lang, Nicholas P, Hauer-Jensen, Martin |
| المصدر: |
Lancet. 08/12/2000, Vol. 356 Issue 9229, p566. 2p. 1 Chart. |
| مصطلحات موضوعية: |
COLON cancer, THALIDOMIDE, DNA topoisomerase I, RECTAL cancer treatment, CHEMICAL inhibitors, THERAPEUTICS |
| مستخلص: |
Irinotecan is the only accepted second-line treatment for colorectal cancer in the USA. Doses are, however, frequently limited by associated late-onset diarrhoea. Thalidomide has antiangiogenic and immunomodulatory properties and is being investigated as an antineoplastic. We did a pilot study of combination therapy with thalidomide and irinotecan for metastatic colorectal cancer. In an interim analysis of nine patients, thalidomide had almost eliminated the dose-limiting gastrointestinal toxic effects of irinotecan, especially diarrhoea and nausea (each p<0.0001), and eight of nine patients were able to complete the chemotherapy course. [ABSTRACT FROM AUTHOR] |
|
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
